Aerogen, Ireland’s largest indigenous medtech company, has announced the establishment of a new manufacturing operation in Shannon resulting in the creation of over 90 new positions.
Aerogen will be partially occupying the former Molex facility building which is now owned by United Metals (T/a UMR group), who purchased the building with the view to getting industries back operating in the facility. Shannon was a very attractive location for Aerogen; “we have had very positive collaborations with industry, academia and service providers in the Mid-West region in the past and we look forward to building on these and creating new relationships in the region” said Dr. Brendan Hogan, Senior Vice President of Engineering & Operations Aerogen.
Minimising the risk of supply of quality drug delivery systems on time to patients worldwide was key in our decision to establish a new facility in Shannon.
We are utilising our significant investment in plant and equipment there as well as having access to a pool of skilled workers and well qualified and competent staff in the Midwest region. New equipment and tooling has been installed and Aerogen will be making further investments there to continue the growth trajectory of the company as it further expands existing business and develops new markets.
This is really great news for Shannon and the entire Mid-West region. Aerogen, which started in Galway, is now a world-leading medtech company and Enterprise Ireland has been proud to support its development in recent years. I know that the excellent relationships built up between industry and third-level institutions in the Mid-West, as well as a very skilled and dedicated workforce were important factors in Aerogen’s decision to locate in Shannon. I wish the company the very best of luck with this expansion.
AerogenAerogen is the world leader in high-performance aerosol drug delivery in the acute care sector reaching over 13 million patients, in more than 75 countries. Aerogen’s unique award-winning vibrating mesh technology is supported by over 300 international patents.
The Aerogen Solo converts liquid drug into a nebulised mist of consistently sized droplets that enable medication to get deep into the patients’ lung. Recommended by multiple international COVID-19 guidance documents, Aerogen is the only globally available closed circuit aerosol drug delivery system for ventilated patients that mitigates the transmission of patient generated infectious aerosol and delivers effective aerosol treatment.